- The P-III U-ACCOMPLISH induction study involves assessing upadacitinib (45 mg, qd) vs PBO in patients with mod. to sev. UC
- The study met its 1EPs @8wks. i.e, patients achieved clinical remission (per Adapted Mayo Score) (31% vs 4%); met its 2EPs i.e clinical response @8wks. & @2wks. (74% vs 25% & 63% vs 26%); endoscopic improvement (44% vs 8%); histologic endoscopic mucosal improvement (37% vs 6%)
- The safety results were consistent with the previous P-III induction study, with no new safety risks observed. Rinvoq is a selective and reversible JAK inhibitor, being studied as an oral therapy for mod. to sev. UC and several other immune-mediated diseases
Click here to read full press release/ article | Ref: Abbvie | Image: Top Employers Institute
The post AbbVie Report Results of Rinvoq (upadacitinib) in Second P-III Induction Study for Ulcerative Colitis first appeared on PharmaShots.